RVL Pharmaceuticals plc Long-Term Debt, Maturity, Year Four
RVL Pharmaceuticals plc had Long-Term Debt, Maturity, Year Four of $45.00 million as of 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour · last filed 2023-03-20
- 2022-12-31: Long-Term Debt, Maturity, Year Four $45.00M.
- 2022-09-30: Long-Term Debt, Maturity, Year Four $45.00M.
- 2022-06-30: Long-Term Debt, Maturity, Year Four $33.00M.
- 2022-03-31: Long-Term Debt, Maturity, Year Four $33.00M.
| Period end | Long-Term Debt, Maturity, Year Four |
|---|---|
| 2022-12-31 | $45.00M 10-K · filed 2023-03-20 |
| 2022-09-30 | $45.00M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $33.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $33.00M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $11.00M 10-K · filed 2022-03-30 |